Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Adenocarcinoma × regorafenib × Clear all

Phase

Status

Unknown 1 Terminated 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Colorectal Neoplasms 9 Carcinoma, Hepatocellular 4 Rectal Neoplasms 2 Neoplasm Metastasis 2 Liver Neoplasms 2 Thrombocytosis 1 Spinocerebellar Degenerations 1 Small Cell Lung Carcinoma 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Physician Education 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Noonan Syndrome 6 1 Neoplasms 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Metastatic Pancreatic Adenocarcinoma 1 Melanoma 1 MSI-H Colorectal Cancer 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid, Accelerated Phase 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Gemcitabine 6 pembrolizumab 5 Carboplatin 5 Capecitabine 5 Pemetrexed 3 Oxaliplatin 3 Irinotecan 3 osimertinib 2 Sunitinib 2 Radiotherapy 2 Paclitaxel 2 Fluorouracil 2 130-nm albumin-bound paclitaxel 2 trifluridine tipiracil drug combination 1 tislelizumab 1 tegafur-gimeracil-oteracil 1 technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1 sintilimab 1 seribantumab 1 selinexor 1 rubitecan 1 regorafenib 1 pralsetinib 1 olaparib 1 niraparib 1 linifanib 1 ixabepilone 1 ganitumab 1 eribulin 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03722108 2023-10-16

REGIRI

UNICANCER

Phase 1/2 Terminated

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡